副教授，硕士生指导教师

中国协和医科大学生物化学与分子生物学博士研究生毕业(2008)，北京大学肿瘤医院暨北京市肿瘤防治研究所消化肿瘤内科副研究员、副教授。主持或主要参与多项国家或省部级课题，协助指导研究生近40名，在《Oncogene》、《Eur J Cancer》、《Scientific Reports》、《BMC Cancer》、《Medical Oncology》、《World J Gastroenterology》等发表论文近20篇，研究论文多次获奖。

电话：88196747 邮箱：gaojing_pumc@163.com

主要研究方向、成就

从事消化系统肿瘤的基础与转化研究工作，主攻方向为胃癌分子分型指导的个体化治疗，探索新的药物靶点，药物耐药机制及逆转耐药研究，药物临床前研究平台(人源化PDX模型)建立及疗效研究。在国内外首次运用胃镜活检胃癌标本构建了人源化PDX模型，为新药研发及耐药机制探索提供最佳的临床前研究模型;首次发现，miR-34a可通过抑制肠癌细胞的增殖、迁移和侵袭而抑制肠癌术后复发;联合检测MAP-tau与TUBB3表达可预测胃癌紫杉醇敏感性，为分子分型指导的个体化治疗提供依据。

承担课题

1. 国家自然科学基金青年基金：miR-34a在结直肠癌复发及调节5-FU敏感性中的作用与机制(#81301853，2014-2016)

2. 北京大学肿瘤医院科学研究基金：miR-34a在结直肠癌细胞侵袭迁移及调节5-FU敏感性中的作用与机制(# 2013自主2，2013-2014)

3. 中国抗癌协会基金：晚期胃癌中ABCB1 G2677T/A多态性与紫杉醇联合卡培他滨疗效的相关性研究(2012-2013)

代表性论文(第一#或责任作者*)

1. Zhu Y, Tian T, Li Z, Tang Z, Wang L, Wu J, Li Y, Dong B, Li Y, Li N, Zou J, Gao J*, Shen L* (2015) Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Scientific Reports DOI: 10.1038/srep08542

2. Gao J, Li N, Dong Y, Li S, Xu L, Li X, Higashimori A, Li Y, Li Z, Ng, SS, Sung JJ, Shen L, Yu J (2014) miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene doi: 10.1038/onc.2014.348

3. Yu J#, Gao J# Lu Z, Gong J, Li Y, Dong B, Li Z, Zhang X, Shen L* (2014) Combination of MAP-tau and TUBB3 predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. Eur J Cancer 50(13):2328-35

4. He Q#, Gao J#, Ge S, Wang T, Li Y, Peng Z, Li Y, Shen L* (2014) Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo. J Cancer Res Clin Oncol 140:1575-83.

5. Gao J, Zhou J, Li Y, Peng Z, Li Y, Wang X, Shen L* (2013) Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Med Oncol 30(3):630-5.

6. Gao J, Dang Y, Sun N, Li J, Shen L. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients. Med Oncol. 2012;29(5):3039-45.

7. Gao J, Lu M, Yu JW, Li YY, Shen L (2011) Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 11:177-83

8. Gao J, Li YY, Sun PN, Shen L* (2010) Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. World J Gastroenterol. 16(38):4858-64.

9. Gao J, Chen T, Liu J, Liu W, Hu G, Guo X, Yin B, Gong Y, Zhao J, Qiang B, Yuan J, Peng X* (2009) Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia 57(9):989-99.

10. Gao J, Chen T, Hu G, Gong Y, Qiang B, Yuan J, Peng X* (2008) Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity. Biochim Biophys Acta 1778(6):1429-35.